Difference between revisions of "Darbepoetin alfa (Aranesp)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| Line 18: | Line 18: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Erythrocyte growth factors]] |
Revision as of 19:33, 17 May 2014
Also known as epo or erythropoetin.
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Darbepoetin alfa (Aranesp) package insert pages 39-46[1]
- Darbepoetin alfa (Aranesp) patient drug information (Chemocare)[5]
- Darbepoetin alfa (Aranesp) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 1.2 Darbepoetin alfa (Aranesp) package insert
- ↑ Darbepoetin alfa (Aranesp) package insert (locally hosted backup)
- ↑ Aranesp manufacturer's website
- ↑ ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Darbepoetin alfa (Aranesp) patient drug information (Chemocare)
- ↑ Darbepoetin alfa (Aranesp) patient drug information (UpToDate)